

## Drug Monograph

Drug/Drug Class: **Dehydrated Alcohol (alcohol) Injection/ Neurolysis Agent**

Class:

Prepared for: MO HealthNet

Prepared by: ACS, A Xerox Company

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Dehydrated Alcohol Injection consists of not less than 98% by volume of ethanol (ethyl alcohol).

**Manufacturer:** Akorn, Inc. Lake Forest, IL 60045 DA00N Rev. 09/11

**Indications:** Dehydrated Alcohol Injection is indicated for therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (tic douloureux), in patients for whom neurosurgical procedures are contraindicated.

**Costs:** \$39.80 per 5 mL vial of Dehydrated Alcohol Injection Wholesale Acquisition Cost

**Summary of Findings:** MO HealthNet recommends Open Access status for this product.

**Status Recommendation:**  Prior Authorization (PA) Required  Open Access  
 Clinical Edit  PDL

**Type of PA Criteria:**  Increased Risk of ADE  Preferred Agent  
 Appropriate Indications  No PA Required

Prepared By: Katie Wilbers, Pharm. D.  
Date: February 13, 2012